Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Description Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading
etiology for chronic liver disease, affecting> 25% of the US and global populations. Up to 1 …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

As the predominant type of chronic liver disease, the growing prevalence of nonalcoholic
fatty liver disease (NAFLD) has become a concern worldwide. Although obesity plays the …

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents
with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes …

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide, with a global prevalence of approximately 30%. However, the prevalence of …

Lean individuals with NAFLD have more severe liver disease a... : Hepatology Lean individuals
with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study) …

Globally, nearly half of deaths from cirrhosis and chronic liver diseases (CLD) and three-
quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region …

Background & Aims Although approximately 40% of patients with nonalcoholic fatty liver
disease (NAFLD) are nonobese or lean, little is known about the long-term clinical outcomes …